

Isodiol to acquire Biosynthesis Pharma Group

18 December 2017 | News

BSPG produces high-purity, bioactive cannabinoids that are used in pharmaceutical applications.



Global Bioactive Phytoceutical innovator, Isodiol International Inc. has entered into a binding agreement to acquire the Biosynthesis Pharma Group (BSPG). Isodiol specializes in the development of pharmaceutical and wellness products whereas BPSG is an industry leading producer of industrial hemp.

BSPG produces high-purity, bioactive cannabinoids that are used in pharmaceutical applications to benefit those suffering from a range of life-threatening and non-life-threatening illnesses. BSPG is currently conducting clinical trials involving its product through strategic partnerships around the globe.

The BSPG acquisition includes multiple entities that are strategic to the future of Isodiol. Each of these entities are intended to have a distinct purpose within the Isodiol organization, whether it be defined by geography, applicable laws, or line of business.

The company will acquire BSPG for \$12,500,000 to be paid out over 12 months and stock compensation in the amount of \$37,000,000 based on the closing price on December 15, 2017.